<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140970</url>
  </required_header>
  <id_info>
    <org_study_id>14-0514</org_study_id>
    <nct_id>NCT02140970</nct_id>
  </id_info>
  <brief_title>Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal</brief_title>
  <official_title>Double-blind, Placebo-controlled Randomized Controlled Trial of NSAID Prior to Ureteral Stent Removal in a Pediatric Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about whether ibuprofen can reduce pain after removal of a
      ureteral stent more than a placebo. Some patients experience pain after removal of a ureteral
      stent. The investigators plan to learn how often this occurs and whether it can be prevented.

      The investigators hypothesize that children who have a temporary, indwelling ureteral stent
      will experience a significantly less post-operative pain if given a non-steroidal
      anti-inflammatory (NSAID) prior to removal of the ureteral stent when compared to placebo.
      The investigators hypothesize that the incidence of severe post-stent removal pain is similar
      to an adult population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of post-operative severe pain (pain score ≥ 7)</measure>
    <time_frame>24 hours after stent removal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of &quot;significantly worsening&quot; pain</measure>
    <time_frame>24 hours after stent removal</time_frame>
    <description>Incidence of &quot;significantly worsening&quot; pain is defined as any increase ≥ 2 between the pre-operative and post-operative pain scale assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pre- and post-operative pain score</measure>
    <time_frame>24 hours after stent removal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid usage post-operatively</measure>
    <time_frame>24 hours after stent removal</time_frame>
    <description>This will be recorded in equivalents to milligrams intravenous morphine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Disorder of Urinary Stent</condition>
  <condition>Ureteral Spasm</condition>
  <condition>Ureteropelvic Junction Obstruction</condition>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>Liquid ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal</description>
    <arm_group_label>Liquid ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal</description>
    <arm_group_label>Liquid placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 4-17

          -  unilateral ureteral stent placed after ureteropelvic junction obstruction repair or
             treatment of upper tract urolithiasis

        Exclusion Criteria:

          -  bilateral stents

          -  undergoing other concomitant procedure at time of planned ureteral stent removal

          -  indication for stent other than ureteropelvic junction obstruction repair or treatment
             of upper tract urolithiasis

          -  pregnant

          -  developmental delay

          -  allergy to ibuprofen or non-steroidal anti-inflammatory medication class

          -  chronic kidney disease

          -  prior renal transplant

          -  history of nasal polyps

          -  history of asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Campbell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheryl Holbrook</last_name>
    <email>sheryl.holbrook@ucdenver.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffrey Campbell, MD</last_name>
    <email>jeffrey.campbell@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Duncan Wilcox, MD, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vijay Vemulakonda, MD, JD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Cost, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyle Rove, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Chalmers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Bielsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tadros NN, Bland L, Legg E, Olyaei A, Conlin MJ. A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: a prospective, randomised, double-blind, placebo-controlled trial. BJU Int. 2013 Jan;111(1):101-5. doi: 10.1111/j.1464-410X.2012.11214.x. Epub 2012 May 11.</citation>
    <PMID>22578110</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ureteral stent</keyword>
  <keyword>stent pain</keyword>
  <keyword>ureteral spasm</keyword>
  <keyword>NSAID</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>placebo</keyword>
  <keyword>ureteropelvic junction obstruction</keyword>
  <keyword>urolithiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Hydronephrosis</mesh_term>
    <mesh_term>Ureteral Obstruction</mesh_term>
    <mesh_term>Multicystic Dysplastic Kidney</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

